Livzon Pharmaceutical Group Inc. (000513.SZ) News
Track canonical SquawkNews coverage tagged to 000513.SZ, Livzon Pharmaceutical Group Inc.. This hub brings together deduplicated headlines about shenzhen stock exchange, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Livzon Pharmaceutical unit gets NMPA approval for leuprorelin acetate microspheres injection
Reuters reports the unit received an NMPA drug supplementary application approval notice for leuprorelin acetate microspheres for injection 11.25mg (3-month formulation).
EQUITY | Sep 29, 2026, 03:27 PM UTC
M
Livzon Pharma unit gets China NMPA approval for 11.25 mg three-month leuprorelin microspheres
Shanghai Livzon received NMPA clearance to market leuprorelin acetate microspheres injection 11.25 mg, adding a three-month specification to its existing 3.75 mg and 1.88 mg versions. R&D spending for the three-month for
EQUITY | Sep 29, 2026, 10:46 AM UTC